《Cytokine-induced killer cell combination with TACE in the treatment of hepatocellular cancers：a meta-analysis.》.pdf

inese-GermanIClinOncol October2013，Vo1．12，No．10，P459-P46 I10．1007／s10330—013—1219—6 killercelIcombinationwithTACE inthetreatmentofhepat0Ce¨Ularcancers： ameta—anaIySiS水 BiaoChen，XimingXu，MiaoXiang，JiaoYang，TingtingYu，YiHu CancerCenter，RenminHospitalofW uhanUniversity，W uhan430060，China Received：7July2013／Revised：8August2013／Accepted：15September2013 @HuazhongUniversityofScienceandTechnologyandSpringer-VerlagBerlinHeidelberg2013 Abstract Objective：Theaim oflhestudywasloevaluatetheefficacyandsafelvofcytokine．inducedkillerfCIK)celI combinedwithlranscatheterarterialchem0emb0Iizalion(TACE)therapyinlhelreatmenlofhepatocellularcarcinoma(Hcc)． Methods：Randomizedcontrolledtrials(RCTs)onCIKcellscombinationwithTACEbased-therapywereidentifiedbyelec． 1ronicsearchesintheCochraneLibrary，MEDLINE。Pubmed，Waning，VIP,CNKlandotherelectronicdalabases．Wein． cludedanyRCTsevaluatingCIKcellcombinationwithTACEf0rthetreatmenlofhepatocellularcancers．ThequalityofRCTs meetinginclusioncriteriawasevaluatedanddataonshort-termandlong-term curativeeffects．qualityofIife．Iiverfunction andimmunologicfunctionwereextracted．Forquantitativedata．weconductedmeta．analysiswithReMan5．1softwareand lheGRADESystemwasusedtoratelhelevelofevidenceandstrengthofrecommendation．Forqualitativedata．datamainly adopteddescriptivemethods．Results：The9RCTsinvolving870casesmeetinglheinclusioncriteriawereincluded．The meta-analysisshowedsignificantsurvivaIbenefifon0．5一yearsurvivaJratefRR=1．51，95％CI，1．35-1．69，P0．00001)Infa． vorofCIKbasedtherapy．Thiseffectwasconsistenlalotherprospectivedates，including1一yearsurvivaIrate(RR=2．30，95％ Cl，1．94—2．72，P0．00001)．2-yearsurvivalrate(RR=7．03，95％CI．3．83-12．91，P0．0001)．Meanwhile，lheCIK．based